REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website ...

REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. “We’re thrilled to place these e ...

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a fireside chat on Wednesday, June 5, 2024, at 11:30 am ET. A live webcast of the event will be available here and in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived ...

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API Manufacturing" at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. The panel will take place o ...

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API Manufacturing" at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. The panel will take place o ...

财务数据和关键指标变化 - 公司2024年第一季度总收入为1.71亿美元,同比增长32% [61] - 产品收入为9.6百万美元,同比增长14% [61] - 研发收入为7.5百万美元,其中包括与罗氏公司签订的6百万美元双链DNA连接酶协议 [62] - 产品毛利率提升至49%,较上年同期的46%有所改善 [62] 各条业务线数据和关键指标变化 - 公司产品收入中,约37%来自3个主要的商业制药产品,较上年同期的72%大幅下降,反映出公司收入来源的多元化 [65] - 约5%来自酶供应和其他商业批准产品,19%来自仿制药,34%来自临床试验阶段的项目,5%来自生命科学和其他项目 [65] 各个市场数据和关键指标变化 - 公司正在与中型制药企业和大型生物技术公司建立新的筛选项目,预计将在今年下半年转化为研发收入 [79][80] - 公司正在推出双链RNA连接酶筛选服务,以及eco RNA连接酶试剂盒,简化客户的筛选过程,并有望增加未来的定制项目 [52][53] 公司战略和发展方向及行业竞争 - 公司正在开发酶促合成NQP和靶向基团的创新解决方案,以降低成本并提高产品质量 [35][36][37] - 公司的ECO合成创新实验室将为客户提供从小试到GMP生产的全流程服务,并为公司未来的GMP生产能力奠定基础 [56][57] - 公司的CodeEvolver定向进化平台结合人工智能和丰富的数据,为公司带来竞争优势 [23] 管理层对经营环境和未来前景的评论 - 公司2024年第一季度业绩良好,符合预期,预计全年收入和毛利率将保持稳定增长 [11][67] - 公司有望在TIDES大会上实现全长RNA寡核苷酸的酶促合成,这是一个重要的技术里程碑 [12][13] - 公司看好双链RNA连接酶业务的发展前景,认为这将成为客户采用酶工艺的重要桥梁 [16][17][18][19] 问答环节重要的提问和回答 问题1 **Matt Stanton 提问** 公司在实现全长RNA寡核苷酸合成方面还有哪些最后的障碍? [77] **Stefan Lutz 回答** 公司希望在TIDES大会上不仅展示成功合成,还要分享相关的分析数据和纯度情况,这需要额外的时间来完成实验 [78] 问题2 **Evan Stampler 提问** 公司是否已经在最初的指引中考虑了双链RNA连接酶订单,以及是否还有其他潜在客户? [94][95] **Kevin Norrett 和 Sri Ryali 回答** 这个订单没有包含在最初的指引中,但公司有信心维持此前给出的全年收入指引区间。公司正在积极拓展双链RNA连接酶的客户群,预计未来6个月内会有4-5个新客户加入 [96][97] 问题3 **Matt Hewitt 提问** 公司的双链RNA连接酶筛选服务在未来2-4年内会有怎样的增长? [102][103][104] **Stephen Dilly 和 Kevin Norrett 回答** 这项筛选服务主要是为了让客户更容易将公司的连接酶纳入自身的工艺流程。公司预计从首次接触到实现商业级生产供应的时间会大幅缩短,因为客户会在较晚期的开发阶段采用这种方式 [103][104][106]

Q1 2024 Results May 2, 2024 We engineer enzymes Forward Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) ________________________ ...

Exhibit 99.1 Codexis Reports First Quarter 2024 Financial Results Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 2, 2024 -- Codexis, Inc. (NASDAQ: CDXS), a leading ...

任命战略顾问委员会成员 - Codexis公司宣布任命Carole Cobb为战略顾问委员会成员[1] - Carole Cobb在生物技术领域拥有超过40年的经验，曾担任GreenLight Biosciences的首席运营官[2] - Codexis的战略顾问委员会由行业专家组成，包括John Maraganore、Masad Damha、Jim Lalonde和Carole Cobb[4]